Custom Search

Friday, October 4, 2013

Tigecycline drug safety alert by US FDA

Tigecycline an antibiotic which was considered very effective against resistant strains of microorganisms and was liberally used to treat serious infections like ventilator associated pneumonia and diabetic foot infections is required to provide a boxed warning . A warning which is considered most prompt and effective for a drug.
A safety alert is given by US FDA for the use of Tigecycline as a study have provided data indicating increased number of losses of lives in patients given Tigecycline for treating ventilator associated pneumonia through intravenous injection, compared with other antibiotics . This could be again due to development of resistance for Tigecycline as well.

Tigecycline is not approved by US FDA for treating ventilator associated pneumonia and diabetic foot infection. Tigecycline is approved for treating community-acquired bacterial pneumonia (CABP), complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI).

Tigecycline an antibiotic developed around tetracycline backbone belongs to a novel class of antibiotics Glycylcycline, it was developed to over come antibiotic resistance developed against tetracycline group of antibiotics by resistant strains of Staphylococcus aureus and Acinetobacter baumannii and to metalo- betalactumase enzyme ( ezyme which makes bacteria resistant to wide range of betalactum antibiotics).
Tigecycline could easily counteract on such infection even an infection of multidrug resistant strain of Enterobacteriaceae could be eliminated with Tigecycline, which might be the reason tigacycline gained wide application in medicine for treating infections such as diabetes foot infection, and ventilator associated pneumonia.

US FDA has given safety alert for using Tigecycline cautiously when there is no alternative antibiotic available.

No comments:

How to successfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.

1.You should write your Email ID in the box provided and push the subscribe button

2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Check our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.

Enter your email address get our articles by email whenever this website is updated

Delivered by FeedBurner

Join the list of our readers from Universities ,Research and
Development centers Pharmaceutical Companies from all over the world.

Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: Website:
Copyright © 2008-2020 all rights reserve